

The anti-cancer drug, phenoxodiol, kills primary myeloid and lymphoid leukemic blasts and rapidly proliferating T cells

Patrics M. Herst,¹ Joanne E. Davis,² Paul Neeson,² Michael V. Berridge,¹ and David S. Ritchie²

¹Malaghan Institute of Medical Research, Wellington, New Zealand, and ²Haematology and Immunology Translational Research Laboratory, The Cancer Immunology Research Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

Citation: Herst PM, Davis JR, Neeson P, Berridge MV, and Ritchie DS. The anti-cancer drug, phenoxodiol, kills primary myeloid and lymphoid leukemic blasts and rapidly proliferating T cells. *Haematologica* 2009;doi:10.3324/haematol.2008.003996

Online Supplementary Table S1. Characteristics of leukemic blasts from bone marrow samples.

Patient	Disease Specifics	% Viable Blasts*
1	B-cell ALL	7
2	B-cell ALL	14
3	ALL unspecified	16
4	T-cell ALL	19
5	APML	20
6	AML biphenotypic leukemia	23
7	B-cell ALL	25
8	B-cell ALL	29
9	AML	32
10	AML M1	36
11	B-cell ALL	37
12	AML	39
13	B-cell ALL	40
14	AML	44
15	AML M5	49
16	AML	55
17	AML	57
18	APML	58
19	AML	62
20	AML M5	62
21	AML M5	67
22	AML	71
23	AML	75
24	AML	88
25	AML	92
26	AML	95
27	AML	96
28	AML	97
29	AML	99
30	AML	99

* % viable blasts after 24 h 10 mM phenoxodiol/%viable blasts after 24 h 0.1% DMSO.